Abbott reports second-quarter earnings per share $0.30 from continuing operations

Reports second-quarter 2020 results, exceeds analysts' expectations.sees fy 2020 adjusted earnings per share at least $3.25 from continuing operations excluding items.sees fy 2020 gaap earnings per share at least $2.00 from continuing operations.q2 adjusted earnings per share $0.57 from continuing operations.q2 gaap earnings per share $0.30 from continuing operations.q2 earnings per share estimate $0.41 -- refinitiv ibes data.laboratories - projects full-year 2020 diluted eps from continuing operations on a gaap basis of at least $2.00.laboratories - sees full-year adjusted diluted eps from continuing operations of at least $3.25.laboratories - q2 worldwide sales of $7.3 billion down 8.2% on reported basis & 5.4% on organic basis, which excludes impact of foreign exchange.laboratories - quarterly medical devices sales $2.42 billion, down 21.2% on reported basis.in core laboratory diagnostics, lower routine diagnostics testing partially offset by sales of covid-19 laboratory-based tests for detection of igg antibody in quarter.laboratories qtrly diagnostics sales $1.99 billion, up 4.7% on a reported basis.laboratories - saw significant improvements in growth trends throughout quarter in business areas that were initially most impacted by pandemic.
ABT Ratings Summary
ABT Quant Ranking